WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4] diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 2, 2005, Pages 862-869

  Dunlop, John ^a   Sabb, Annmarie L ^a   Mazandarani, Hossein ^a   Zhang, Jean ^a   Kalgaonker, Sachin ^a   Shukhina, Eugenia ^a   Sukoff, Stacey ^a   Vogel, Robert L ^a   Stack, Gary ^a   Schechter, Lee ^a   Harrison, Boyd L ^a   Rosenzweig Lipson, Sharon ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 CHLORO 5 METHYL 1 (5 QUINOLYLCARBAMOYL)INDOLINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALPHA 1 ADRENERGIC RECEPTOR; ANTIOBESITY AGENT; CALCIUM; CYCLOPENTANE DERIVATIVE; DIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; INDOLE DERIVATIVE; IODINE 125; KETANSERIN; PARTIAL AGONIST; RECEPTOR SUBTYPE; SB 215505; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; WAY 162545; WAY 163907; WAY 163909;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; FOOD INTAKE; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APPETITE DEPRESSANTS; AZEPINES; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; HUMANS; INDOLES; MALE; MICE; MICE, INBRED C57BL; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS;

EID: 20944441963     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.075382     Document Type: Article

References (36)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, and Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
2. Barnes NM and Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
3. 2 receptor subtypes: a family re-united? Trends Pharmacol Sci 16:105-110.
4. Berendsen HH (1995) Interactions between 5-hydroxytryptamine receptor subtypes. Pharmacol Ther 66:17-37.
5. 2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem 3:885-897.
6. 2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Chem 40:2762-2769.
7. Cowen PJ, Sargent PA, Williams C, Goodall EM, and Orlikov AB (1995) Hypophagic, endocrine and subjective responses to m-chlorophenylpiperzine in healthy men and women. Hum Psychopharmacology 10:385-391.
8. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81.
9. 1C receptor activation: a key step in the initiation of migraine? Trends Pharmacol Sci 10:307-309.
10. 2C receptors but not by sympathomimetic effects. Neuropharmacology 33:457-465.
11. 2C receptor agonist in Zucker rats. Brain Res 1011:221-227.
12. 2C receptor mutant mice. Ann NY Acad Sci 861:74-78.
13. 1B receptors. Psychopharmacology 96:93-100.
14. 1C antagonists indicate that receptors mediated mCPP-induced hypophagia. Br J Pharmacol 103:2016-2020.
15. 2B mediated. Neuropharmacology 37:1603-1610.
16. 2C receptor antagonist. Neuropharmacology 36:609-620.
17. 2C receptor agonist. Eur J Pharmacol 283:37-43.
18. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129-1135.
19. Leyson D and Kelder J (1998) Ligands for the 5-HT2C receptor as potential antidepressants and anxiolytics, in Trends in Drug Research (van der Groot J ed) pp 49-61, Elsevier, Amsterdam.
20. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913-924.
21. Masand PS (2000) Weight gain associated with psychotropic drugs. Expert Opin Pharmacother 1:377-389.
22. 2C receptor agonist, reduces feeding in rodents and produces weight loss in humans. Soc Neurosci Abstr 27:309.2.
23. 2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur J Pharmacol 325:9-12.
24. 2C receptor gene. Nat Med 4:1152-1156.
25. 2C agonist WAY-161503. FASEB J 14:A1321.
26. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
27. 2C receptor. Bioorg Med Chem Lett 14:2603-2607.
28. Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, and Garattini S (1979) m-Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn-Schmiedeberg's Arch Pharmacol 308:159-163.
29. 1C receptor activation by hallucinogenic drugs. Psychopharmacology 105:340-346.
30. 2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133:209-312.
31. 2C receptors. Nature (Lond) 374:542-546.
32. Vickers SP, Benwell KR, Porter EH, Bickerdike MJ, Kennett GA, and Dourish CT (2000) Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 130:1305-1314.
33. 2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 167:274-280.
34. Walsh AE, Smith KA, Oldman AD, Williams C, Goodall EM, and Cowen PJ (1994) m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology 116:120-122.
35. Welmaker GS, Nelson JA, Sabalski JE, Sabb AL, Potoski JR, Graziano D, Kagan K, Coupet J, Dunlop J, Mazandarani H, et al. (2000) Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a] quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg Med Chem Lett 10:1991-1994.
36. Whitaker R (2000) Atypical antipsychotics: a modest advance in treating schizophrenia. Spectrum. Life Sci Decision Resource 2:1-9.